

Topical Ophthalmic Delivery of Quercetin and Resveratrol using Elastin-like Recombinamer Nanoparticles

L. Krstić¹, R. Vallejo^{2,3}, S. Rodríguez-Rojó², A. Girotti⁴, F. J. Arias³,
M.J. González García^{1,4}, Y. Diebold^{1,4}

¹Ocular Surface Group, Instituto de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, 47011Valladolid, Spain;
²BioEcoUVA, Research Institute on Bioeconomy, PressTech Group, University of Valladolid, Department of Chemical Engineering and Environmental Technology, Escuela de Ingenierías Industriales, Sede Mergelina, 47011 Valladolid, Spain
³Smart Devices for NanoMedicine Group, University of Valladolid, LUCIA Building, Paseo Belén 19, 47011 Valladolid, Spain
⁴Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid Spain

INTRODUCTION

Natural polyphenols, **Quercetin (QUE)** and **Resveratrol (RSV)**, have been proven to be efficient in the treatment of ocular surface diseases related to oxidative stress, like **Dry Eye Disease (DED)**^{1,2}. Unfortunately, their application as a topical ophthalmic treatment is limited by their poor physico-chemical characteristics. Therefore, our aim was to encapsulate QUE, RSV or the combination of both polyphenols into **Elastin-like recombinamer nanoparticles (ELR-NPs)** and test their biocompatibility and antioxidant activity *in vitro* on a Human Corneal Epithelial (HCE) cell line and assess their penetration of corneal tissues *ex vivo* on excised porcine eyes.

METHODS


Cell Viability




- The **biocompatibility** of ELR NPs containing QUE, RSV or both with HCE cells was assessed through the **XTT assay**.

Intracellular ROS Scavenging Activity

- The ability of the formulations to **scavenge intracellular ROS** was tested in UV-B exposed and unexposed (control) HCE cells, using **H₂DCFDA**, a fluorescent indicator of ROS.



Ex vivo Penetration of Corneal Tissues




- To evaluate the penetration through *ex vivo* porcine corneal tissues, **NPs were loaded with Nile Red**, a fluorescent probe used as **model of hydrophobic drug**. Free Nile Red was used as a control.

RESULTS

- The **concentration of NPs** used for the experiments was as follows: **ELR:QUE 5-50µM**, **ELR:RSV 25-300 µM** and **ELR:QUE:RSV 5-50 µM**.


Cell Viability

- None** of the NPs affected the **viability** of the HCE cells.
- As **negative and positive controls** **cell medium** and **BAK (0.005%)** were used




Intracellular ROS Scavenging

- UV-B induced intracellular **ROS** were **significantly decreased** by all types of NPs.
- This response was **dose dependent**.
- Cells exposed to UV-B are marked with a (●) in the graphs; while the unexposed ones with (□).



Ex vivo Penetration of Corneal Tissues



- Encapsulated Nile Red** showed **improved penetration** of porcine corneal tissues compared to the **pure compound**.
- The penetration improvement was **time-dependent**.
- ELR NPs (green fluorescence)** **remain on the epithelium surface**, releasing the payload Nile Red in the corneal tissues
- E- Corneal Epithelium; S- Corneal Stroma**

All data are means ± SEM of three independent experiments. * p<0.05, ** p<0.01, *** p<0.001 in comparison to the control. # p<0.05, ## p<0.01, ### p<0.001 intergroup comparison. The statistical analysis of data was performed via ANOVA followed by Games-Howell or Tukey's post-hoc tests.

CONCLUSIONS

- All NPs tested were **biocompatible** with HCE cell line.
- All formulations showed **good ability to scavenge** intracellular ROS species.
- Nile Red loaded in NPs had better ex vivo penetration** of porcine corneas in respect to the free fluorophore.

References: 1- Abengózar-Vela A et al. Quercetin and Resveratrol Decrease the Inflammatory and Oxidative Responses in Human Ocular Surface Epithelial Cells. *Invest. Ophthalmol. Vis. Sci.* 2015;56(4):2709-2719 2- Abengózar-Vela A et al., Topical Quercetin and Resveratrol Protect the Ocular Surface in Experimental Dry Eye Disease *Ocul Immunol Inflamm.* 2019;27(6):1023-1032

Financial support: EU, H2020 Marie Skłodowska-Curie Actions ITN "IT-DED3" (grant agreement No 765608); Regional Government of Castilla y León and the EU-FEDER program (CLU-2019-04); RTI2018-094071-B-C21 (Spanish Ministry of Science, Innovation and Universities and European Regional Development Fund).
Commercial Relationships Disclosure: LK, RV, SRR, AG, FJA, MJGG, YD : None.